Three-Year Safety and Efficacy of the INCRAFT Endograft for Treatment of Abdominal Aortic Aneurysms: Results of the INSIGHT Study.

Autor:	Torsello G; Department of Vascular Surgery, St. Franziskus Hospital, Muenster, Germany., Bertoglio L; Division of Vascular Surgery, IRCCS San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy., Kellersmann R; Clinic and Polyclinic for General, Visceral, Vascular and Pediatric Surgery, University Hospital Würzburg, Würzburg, Germany., Wever JJ; Department of Vascular Surgery & Interventional Radiology, Haga Hospital, The Hague, The Netherlands., van Overhagen H; Department of Vascular Surgery & Interventional Radiology, Haga Hospital, The Hague, The Netherlands., Stavroulakis K; Department of Vascular and Endovascular Surgery, University Hospital Münster, Münster, Germany.; Department of Vascular and Endovascular Surgery, Ludwig-Maximilian-University Hospital, Munich, Germany.
Jazyk:	angličtina
Zdroj:	Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists [J Endovasc Ther] 2023 Nov 30, pp. 15266028231214162. Date of Electronic Publication: 2023 Nov 30.
DOI:	10.1177/15266028231214162
Abstrakt:	Purpose: Preliminary results of the INSIGHT study showed that the low-profile INCRAFT Abdominal Aortic Aneurysm (AAA) Stent-Graft System was safe and effective in the endovascular aneurysm repair (EVAR). This study aimed to assess the durability and the midterm effectiveness of EVAR using the INCRAFT System in the framework of a multicenter, prospective, open-label, post-approval study. Materials and Methods: Between 2015 and 2016, 150 subjects from 23 European centers treated with the INCRAFT System for an infrarenal AAA were included. Clinical and radiologic data were prospectively collected and analyzed using protocol-specified, monitored follow-up clinic visits at 1, 6, and 12 months post-implantation and annually after that. The clinical success at 3 years was determined. Freedom from overall and aneurysm-related mortality, type I endoleak, secondary interventions, and aneurysm sac enlargement through 3 years were evaluated. Kaplan-Meier estimates were used for late outcomes. An independent clinical events committee reviewed all events. The CT (computed tomography) scans through 1 year were reviewed by an independent core laboratory. Results: The primary clinical success rate at 3 years was 84.0% (126/150). There were no aneurysm-related deaths, endograft migration, or aneurysm-related ruptures through 3 years. Stent fracture was detected in 2 subjects (1.3%) without clinical sequelae. Over 3 years, freedom from overall mortality was 89.4%, freedom from secondary interventions was 80%, and freedom from aneurysm sac enlargement was 96.5%. The 3-year freedom from type IA and IB endoleaks was 93.3% and 98.6%, respectively. Conclusions.: In a multicenter real-world study setting, the use of a low-profile INCRAFT device for AAA is associated with sustained clinical success and low rates of reinterventions through 3 years. Clinical Impact: Low-profile endografts have broadened the spectrum of patients with anatomic suitability for endovascular repair of abdominal aortic aneurysms (AAA). However, questions remain regarding the durability of the repair. The INSIGHT study evaluated the use of the INCRAFT System in routine real-world clinical practice, including patients with complex anatomies. The treatment was safe and effective. The results showed sustained clinical success over 3 years, with no aneurysm-related deaths or ruptures, and a high rate of intervention-free survival at 3 years. Despite the low-profile design of the endograft, the midterm results demonstrate the durability of AAA repair using the INCRAFT System.ClinicalTrials.gov Identifier: NCT02477111. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G.T. is a consultant for Cordis and has received educational grants from Medtronic, Cook, Gore, Boston Scientific, and Biotronik, and is CEO and cofounder of Vascupedia and the Foundation for Cardiovascular Research and Education. L.B. has been a consultant for Cordis. R.K. received honoraria from W.L. Gore and C.R. Bard. J.J.W. is a consultant for Cordis and cofounder of the Haga Vascular Research Foundation. H.v.O. is a Cordis and Boston Scientific consultant and cofounder of the Haga Vascular Research Foundation. K.S. has consulted for Phillips, Shockwave, and Terumo; received honoraria from Medtronic, Boston Scientific, and Biotronic; and is a cofounder of Vascupedia and the Foundation for Cardiovascular Research and Education.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu